Subjects was Grouped for Clinical Test on the Quadrivalent Meningococcal Conjugate Vaccine (MCV4) — Another Key Product of AIM Vaccine
This product is one of the global top 10 vaccines. It employs polysaccharide protein chemical coupling technology to bind four common pathogenic meningococcus polysaccharides, i.e. A, C, W135, and Y to carrier protein CRM197 via covalent bonds respectively, which can induce children below 2 years old to produce immune response and thus provide protection for this group of people.
ACYW 123 meningococcal polysaccharide vaccine (MPSV4), a commercialized product of AIM Vaccine, adopts mature polysaccharide purification technology. Several key technical indicators, including acetoxy group, phosphorus content, distribution of molecular sizes, and bacterial endotoxin, are better than the standard specified in Chinese Pharmacopoeia, European Pharmacopoeia and WHO Regulations. The polysaccharide used in MCV4 has been prepared by using such technology and the product continues to meet the high standard.